Study of Adalimumab Administered as Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated With Methotrexate

Study Identifier
M02-573
CT.gov Identifier
NCT00647920
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Rheumatoid Arthritis
    • Study Drug
  • adalimumab
  • placebo
    • Phase
    CSR.ORG
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Meet ACR criteria for diagnosis of active RA and have at both screening and baseline visits 6 swollen joints and 9 tender joints.
    Exclusion Criteria:
    - A history of, or current, acute inflammatory joint disease of different origin than RA (e.g., mixed connective tissue disease, seronegative spondyloarthropathy, psoriatic arthritis, Reiter's syndrome, systemic lupus erythematosus or any arthritide with onset prior to age 16 years).

    Protocol Summary

    A Randomized, Double-Blind, Placebo-Controlled, Study of the Adalimumab Administered as

    Subcutaneous Injections in Adult Chinese Rheumatoid Arthritis Subjects Treated with

    Methotrexate

    Study Locations

    Location
    Status
    Location
    Taichung, Taiwan
    Status
    Not applicable